Abstract
The effects of rhGM-CSF in vivo on the myeloid clonogenic cells present in 6 AML patients was evaluated. The relative number of clonogenic cells fell in 4 of the 6 patients. The effects of rhGM-CSF on the percentage of clonogenic cells in S phase and the sensitivity of clonogenic cells to cytosine arabinoside varied among the patients. These effects were not related to the effects of rhGM-CSF on the white blood cell count or on the proliferative rate of the leukemia cell population as a whole.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Blood Cells / drug effects
-
Bone Marrow / pathology
-
Clone Cells / drug effects
-
Cytarabine / pharmacology
-
Gene Expression Regulation, Leukemic
-
Genes, myc
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Hematopoietic Stem Cells / drug effects*
-
Humans
-
Immunologic Factors / pharmacology
-
Immunologic Factors / therapeutic use*
-
Leukemia, Myeloid, Acute / blood
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / pathology
-
Leukemia, Myeloid, Acute / therapy*
-
Middle Aged
-
Neoplastic Stem Cells / drug effects*
-
Oncogenes
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
S Phase / drug effects
-
Tumor Cells, Cultured / drug effects
-
Tumor Cells, Cultured / pathology
-
Tumor Stem Cell Assay
Substances
-
Immunologic Factors
-
Recombinant Proteins
-
Cytarabine
-
Granulocyte-Macrophage Colony-Stimulating Factor